MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592736 | Name: Alverine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alverine is an autonomic agent.

Chemical Structure

Alverine
CAS#150-59-4 (free base)

Theoretical Analysis

MedKoo Cat#: 592736

Name: Alverine

CAS#: 150-59-4 (free base)

Chemical Formula: C20H27N

Exact Mass: 281.2143

Molecular Weight: 281.44

Elemental Analysis: C, 85.35; H, 9.67; N, 4.98

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
5560-59-8 (citrate) 5982-87-6 (HCl) 3686-59-7 (tartrate) 150-59-4 (free base)
Synonym
Alverine
IUPAC/Chemical Name
Benzenepropanamine, N-ethyl-N-(3-phenylpropyl)-
InChi Key
ZPFXAOWNKLFJDN-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3
SMILES Code
CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 281.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro-Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014 Feb;68(2):245-54. doi: 10.1111/ijcp.12333. Epub 2013 Oct 21. PubMed PMID: 24147869; PubMed Central PMCID: PMC4282257. 2: Lee SH, Athavankar S, Cohen T, Piran R, Kiselyuk A, Levine F. Identification of alverine and benfluorex as HNF4α activators. ACS Chem Biol. 2013 Aug 16;8(8):1730-6. doi: 10.1021/cb4000986. Epub 2013 May 29. PubMed PMID: 23675775; PubMed Central PMCID: PMC3922238. 3: Bueno L, Beaufrand C, Theodorou V, Andro-Delestrain MC. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association. J Pharm Pharmacol. 2013 Apr;65(4):567-73. doi: 10.1111/jphp.12021. Epub 2013 Jan 17. PubMed PMID: 23488786. 4: Gupta D, Radhakrishnan M, Kurhe Y. Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety. Eur J Pharmacol. 2014 Nov 5;742:94-101. doi: 10.1016/j.ejphar.2014.08.033. Epub 2014 Sep 6. PubMed PMID: 25199966. 5: Ghosh C, Jha V, Ahir R, Shah S, Shinde CP, Chakraborty BS. A rapid and most sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of alverine and its major metabolite, para hydroxy alverine, in human plasma: application to a pharmacokinetic and bioequivalence study. Drug Test Anal. 2010 Jun;2(6):284-91. doi: 10.1002/dta.130. PubMed PMID: 20564607. 6: Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010 Mar;31(6):615-24. doi: 10.1111/j.1365-2036.2009.04216.x. Epub 2009 Dec 10. PubMed PMID: 20003095. 7: Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014 May 28;20(20):6031-43. doi: 10.3748/wjg.v20.i20.6031. Review. PubMed PMID: 24876726; PubMed Central PMCID: PMC4033443. 8: Han JY, Lee JW, Kim JM, Joo K, Chon U, Lee JI, Jeong S, Lee DH, Kim YS, Min KS. [A case report of alverine-citrate-induced acute hepatitis]. Korean J Hepatol. 2010 Mar;16(1):75-8. doi: 10.3350/kjhep.2010.16.1.75. Korean. PubMed PMID: 20375645. 9: Abysique A, Lucchini S, Orsoni P, Mei N, Bouvier M. Effects of alverine citrate on cat intestinal mechanoreceptor responses to chemical and mechanical stimuli. Aliment Pharmacol Ther. 1999 Apr;13(4):561-6. PubMed PMID: 10215743. 10: Hayase M, Hashitani H, Suzuki H, Kohri K, Brading AF. Evolving mechanisms of action of alverine citrate on phasic smooth muscles. Br J Pharmacol. 2007 Dec;152(8):1228-38. Epub 2007 Oct 15. PubMed PMID: 17934514; PubMed Central PMCID: PMC2190002. 11: Ford AC. Alverine citrate, simeticone, and Rome III irritable bowel syndrome. Aliment Pharmacol Ther. 2010 Apr;31(7):767-8; author reply 768-9. doi: 10.1111/j.1365-2036.2009.04222.x. PubMed PMID: 20415841. 12: Altintaş E, Uçbilek E, Sezgin O, Sayici Y. Alverine citrate plus simethicone reduces cecal intubation time in colonoscopy - a randomized study. Turk J Gastroenterol. 2008 Sep;19(3):174-9. PubMed PMID: 19115153. 13: Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther. 2002 Jun;16(6):1187-95. PubMed PMID: 12030962. 14: Arhan M, Koklu S, Koksal AS, Yolcu OF, Koruk S, Koruk I, Kayacetin E. Alverine citrate induced acute hepatitis. World J Gastroenterol. 2004 Aug 1;10(15):2303-4. PubMed PMID: 15259090; PubMed Central PMCID: PMC4724969. 15: Coelho AM, Jacob L, Fioramonti J, Bueno L. Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. J Pharm Pharmacol. 2001 Oct;53(10):1419-26. PubMed PMID: 11697552. 16: Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012 Apr-Jun;77(2):82-90. doi: 10.1016/j.rgmx.2012.04.002. Epub 2012 Jun 5. Review. PubMed PMID: 22672854. 17: Beyazit Y, Koklu S, Ozturk ZA, Yüksel O, Ibis M, Arhan M, Gultuna S, Sezer S, Yuksel I, Babali A. Inclusion of a spasmolytic in bowel cleansing: a prospective randomized study. Gastroenterol Nurs. 2011 Sep-Oct;34(5):352-5. doi: 10.1097/SGA.0b013e318229bc90. PubMed PMID: 21979395. 18: Lee KJ. Pharmacologic Agents for Chronic Diarrhea. Intest Res. 2015 Oct;13(4):306-12. doi: 10.5217/ir.2015.13.4.306. Epub 2015 Oct 15. Review. PubMed PMID: 26576135; PubMed Central PMCID: PMC4641856. 19: Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. Br J Clin Pract. 1986 Jul;40(7):276-8. PubMed PMID: 3527247. 20: Malka D, Pham BN, Courvalin JC, Corbic M, Pessayre D, Erlinger S. Acute hepatitis caused by alverine associated with anti-lamin A and C autoantibodies. J Hepatol. 1997 Aug;27(2):399-403. PubMed PMID: 9288616.